The present work aimed to study safety and efficacy of
sirolimus in combination with either low dose tacrolimus or
mycophenolate mofetil in live donor kidney transplant recipients.
A total of 80 patients of either sex aging 18 years
with end-stage renal disease who had undergone live donor
renal allotransplantation were recruited into the study. They
were randomly divided into two groups; group A patients
received sirolimus in a dose of 10 mg/day for 3 days after
surgery then maintained on 5 mg/day. In addition, they received
tacrolimus and steroids. Group B patients received sirolimus
in a dose of 10 mg/day, mycophenolate mofetil and steroids.
All patients were followed up for 12 months clinically and
by laboratory, radiologic and histopathologic evaluation. The
study showed that excellent one year kidney transplant outcomes
can be achieved by sirolimus administration especially
with avoidance of calcineurin inhibitors. Longer follow-up
is required to study the impact on graft integrity and eventual
graft survival and chronic rejection rates. |
